Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

Charles G. Drake, MD, PhD
Published Online: Friday, Apr 28, 2017



Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Currently, there are 4 immunotherapy agents that have data in bladder cancer: 2 PD-L1 antibodies—atezolizumab (Tecentriq) and durvalumab—and 2 PD-1 antibodies, which are nivolumab (Opdivo) and pembrolizumab (Keytruda).

  Drake says that these 4 drugs look very similar in terms of response rates and adverse events. Some suggest that anti–PD-L1 might be better tolerated, Drake adds, but those opinions are based on cross-trial comparisons.
 


Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Currently, there are 4 immunotherapy agents that have data in bladder cancer: 2 PD-L1 antibodies—atezolizumab (Tecentriq) and durvalumab—and 2 PD-1 antibodies, which are nivolumab (Opdivo) and pembrolizumab (Keytruda).

  Drake says that these 4 drugs look very similar in terms of response rates and adverse events. Some suggest that anti–PD-L1 might be better tolerated, Drake adds, but those opinions are based on cross-trial comparisons.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Renal Cell Carcinoma in an Era of Rapid Discovery: Key QuestionsJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x